Cipla USA, Inc. (“Cipla”) announces the launch of an authorized generic version of Aloxi® in the United States under applicable agreements with Helsinn Healthcare SA, in response to the at-risk launch by Teva.
Helsinn Healthcare SA currently manufactures and markets Aloxi® in the United States through its licensee Eisai Inc. and its affiliate Helsinn Therapeutics (US) Inc. Aloxi® containing palonosetron hydrochloride injections (Eq. 0.25 mg base/5 ml) is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy and for prevention of acute nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy.
According to IMS Health, Aloxi® brand had U.S. sales of approximately $460M for the 12-month period ending November 2017.
Cipla’s Authorized Generic of Aloxi® is available for shipping immediately.
